Everest Group EG · NYSE
$389.10 +2.03% (+$7.75)
Summary
66 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 36% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- It bought back its own shares for $818.0M in the last fiscal year, 5.6% of its market value.
What to watch
- Analysts expect revenue to fall by 10% this fiscal year.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 7.6 USD for 1 USD of yearly profit. Over the last five years it was 11.1 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 13% a year. For the next fiscal year analysts expect revenue to fall by 10%. Earnings per share grew by 36% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 71 USD
- Sales and administration 13 USD
- Taxes and other 3.9 USD
- Net profit 11 USD
Net profit, industry median (Insurance - Reinsurance) 9.9 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 2.10%
- Paid out of profit
- 16%
- Raised in a row
- 4 years
You receive $8.00 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 8
- Hold 14
- Sell 0
Today's price within the analysts' price targets
The average target of $412.8 is 6.1% above today's price. 36% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Reinsurance 75%
- Insurance 24%
- Other Operating Segment 1.3%
By region
The company reports no revenue by region.
Reinsurance brings in 75% of revenue.
Segments in detail